Literature DB >> 1979044

From noncompliance to collaboration in the treatment of schizophrenia.

P W Corrigan1, R P Liberman, J D Engel.   

Abstract

Although effective treatment for schizophrenia is available, patients' compliance with treatment prescriptions is notoriously poor. The authors reframe compliance as a collaborative relationship in which both the patient and practitioner assume responsibility for producing a treatment regimen to which the patient can adhere. Barriers that prevent a partnership in treatment may be related primarily to treatment techniques, to characteristics of the patient and his family, to the patient-clinician relationship, or to the treatment delivery system. A comprehensive approach to addressing these sources of noncompliance includes specific skills that can be acquired by the patient, family members, and the practitioner.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979044     DOI: 10.1176/ps.41.11.1203

Source DB:  PubMed          Journal:  Hosp Community Psychiatry        ISSN: 0022-1597


  30 in total

1.  Hospitalized psychiatric patients' resistance to routine medical care.

Authors:  Robert Eilers
Journal:  Adm Policy Ment Health       Date:  1994-05

Review 2.  A clinical review of cognitive therapy for schizophrenia.

Authors:  Neil A Rector; Aaron T Beck
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

3.  Measuring strategies used by mental health providers to encourage medication adherence.

Authors:  Beth Angell
Journal:  J Behav Health Serv Res       Date:  2006-01       Impact factor: 1.505

Review 4.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

5.  Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services.

Authors:  S P Segal; J R Bola; M A Watson
Journal:  Psychiatr Serv       Date:  1996-03       Impact factor: 3.084

6.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

7.  Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.

Authors:  Jose J Mateos; Francisco Lomeña; Eduardo Parellada; Mireia Font; Emili Fernandez; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

8.  Predictors of smoking cessation group treatment engagement among veterans with serious mental illness.

Authors:  Letitia E Travaglini; Lan Li; Clayton H Brown; Melanie E Bennett
Journal:  Addict Behav       Date:  2017-07-10       Impact factor: 3.913

Review 9.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Empowerment and serious mental illness: treatment partnerships and community opportunities.

Authors:  Patrick W Corrigan
Journal:  Psychiatr Q       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.